In her final CND as IDPC ED, Ann Fordham reflects on a historic shift: the recognition of harm reduction in UN drug policy debates, amid rising geopolitical tensions, fractured consensus, and a multilateral system under strain.
IDPC considers Resolution 60/26 a landmark affirmation of the Council’s authority to address the human rights implications of drug policy, strengthening the role of the UN human rights system and reinforcing calls for health-, rights- and evidence-based drug policies globally.
The WHO has upheld the coca leaf’s severe international scheduling, maintaining restrictions despite evidence of its safety and longstanding Indigenous use.
IDPC assesses the state of play in global drug policy, reflecting on areas of progress while highlighting new and ongoing challenges, and concluding with recommendations for the future of international drug policy.
As the United Nations embarks on far-reaching institutional reform, a major new report from the International Drug Policy Consortium (IDPC) delivers a stark warning: global drug control is failing.
By recommending that coca remain in the most restrictive category, the WHO has reinforced a decades-old, colonial classification that undermines scientific research and Indigenous rights.
